<![CDATA[Adjuvant Ensartinib Improves DFS in Resected ALK-Positive NSCLC]]>

Phase 3positiveensartinibPositive

AI Analysis

Summary

Phase 3 trial of adjuvant ensartinib demonstrated significant improvement in 24-month disease-free survival (86.4% vs 53.5% placebo) in patients with resected ALK-positive NSCLC.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Ensartinib improved 24-month disease-free survival rate to 86.4% vs 53.5% with placebo in resected ALK-positive NSCLC

Importance:7/10

Sentiment:

0.85

oncologyNSCLCALK-positiveadjuvant therapydisease-free survival

Related Companies

$PFE

Read the original article

Published by Cancer Network on July 27, 2026 2:30 PM

Read Original